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DENDRITIC cells are a complex group of mainly bone-
marrow-derived leukocytes that play a role in auto-
immune diseases. The total number of circulating
dendritic cells (tDC), and their plasmacytoid dendri-
tic cell (pDC) and myeloid dendritic cell (mDC1 and
mDC2) subpopulations were assessed using flow
cytometry. The number of tDC and their subsets
were significantly lower in systemic lupus erythema-
tosus patients than in the control group. The count of
tDC and their subsets correlated with the number of T
cells. The number of tDC and pDC subpopulation
were lower in the patients with lymphopenia and
leucopoenia than in the patients without these
symptoms. Our data suggest that fluctuations in
blood dendritic cell count in systemic lupus erythe-
matosus patients are much more significant in pDC
than in mDC, what may be caused by their migration
to the sites of inflammation including skin lesions.
Positive correlation between dendritic cell number
and TCD4
, TCD8
 and CD19
 B cells, testify of their
interactions and influence on SLE pathogenesis. The
association between dendritic cell number and clin-
ical features seems to be less clear.
Key words: Dendritic cells, Lymphocytes, Natural killer
cells, Systemic lupus erythematosus, Disease activity
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Introduction
Systemic lupus erythematosus (SLE) is a multiorgan
disease of connective tissue, considered a model of
autoimmune diseases.
1,2 The disease is characterized
by the production of antibodies directed to compo-
nents of the cell nucleus with a diverse array of
clinical manifestations. For many years SLE has been
considered mainly as B-cell disease resulting from
altered T-cell and B-cell interactions.
3,4 However, a
significant role of dendritic cells (DCs) in the control
of tolerance and immunity has been recently proved,
as has the hypothesis that SLE may be driven through
unabated DC activation.
5
DCs are a group of bone-marrow-derived, lineage-
negative Lin
 , HLA-DR
  cells, which are specialized
for the uptake, transport, processing and presentation
of antigens to T cells.
6 This results in T-cell prolifera-
tion and differentiation with respect to cytokine
production. Moreover, DCs appear to be the only
class of antigen presenting cells that have the
capacity to stimulate the expansion of naive T cells
and thereby initiate primary immune responses. DCs
can also generate regulatory T cells that suppress
activated T cells, a function of probable importance
in autoimmunity.
Basically, two main types of DC have been
identified, the CD11c
  subset called plasmacytoid
dendritic cells (pDC), and the CD11c
  subset, called
myeloid dendritic cells (mDC).
7,8 Plasmacytoid DCs
secrete large amounts of interferon-a (IFN-a), when
stimulated with interleukin (IL)-3 and CD40-L prime
T cells to secrete IL-4 (Th2 cytokine).
9,10 However,
when stimulated by viruses they induce T cells to
produce IFN-g and IL-10. mDC include Langerhans
cells and interstitial DCs.
11 Interstitial DCs express
high levels of non-specific esterases and can induce
the differentiation of naive B cells to plasma cells.
Langerhans cells express CD1a and Birbeck granules,
while interstitial DCs express coagulation activation
factor XIII.
10 More recently, a panel of monoclonal
antibodies (mAbs) that identify four presumably
novel human peripheral blood DC antigens (BDCA-
1, BDCA-2, BDCA-3 and BDCA-4) have been
identified.
12 16 The BDCA-1 (CD1
 ) antigen is
specifically expressed on cells that are CD11c
bright,
CD123
dim, and represent a major subset of mDC
(mDC1) in human blood.
12,16 BDCA-3 is restricted to
a small population of myeloid CD123
 , CD11c
  DC
(mDC2).
14 In fresh human blood, expression of
BDCA-2 and BDCA-4 is restricted to plasmacytoid,
CD123
 , CD11c
  peripheral blood DCs.
12 So far,
there are no data available on quantitative character-
istics of these DC subsets and their correlation with
clinical and laboratory symptoms in SLE patients.
DCs have been implicated in the induction of
autoimmune diseases and have been identified in
lesions associated with several autoimmune inflam-
matory diseases.
17 Recently, several evidences have
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171been obtained that interplay between DC subsets
might have an important role in SLE pathogenesis.
5,10
In particular, serum from SLE patients can induce DCs
from monocytes, which are able to capture apoptotic
cells and present their antigen to autologous T cells.
18
This observation may indicate that SLE blood creates
environment inducing DC differentiation. It has been
shown that the DC-inducing property of SLE serum is
mediated by IFN-a.
5 On the other hand, pDC are the
major cellular source of IFN-a in the blood.
19,20
Moreover, considerable alterations of DCs and their
particular subsets have been found in SLE patients,
including reduction of mDC by an average of 80).
20
In pediatric SLE patients undergoing steroid therapy,
DC numbers were over 70) lower than in the
control group.
21 SLE patients who were not treated
with steroids demonstrated a decline number of pDC
by approximately 30). Recently, Shodell et al. have
shown that circulating human DCs are highly sensi-
tive to corticosteroid treatment.
22
In the present study we assessed the total number
of circulating DCs and their plasmacytoid and mye-
loid subpopulations defined by a novel panel of
mAbs directed against BDCA antigens. We also
correlated the number of DCs with peripheral blood
immunocompetent cells that are involved in SLE
pathogenesis. TCD4
 , TCD8
 , B cell (CD19
 ) and
natural killer (NK) cell (CD56
 ) counts. Moreover,
peripheral blood DC subsets were assessed in rela-
tion to several clinical and laboratory parameters as
well as SLE activity.
Patients and methods
Patients
The study group consisted of 53 patients with SLE (49
females and four males), and 33 sex-matched and
age-matched healthy volunteers. The mean age of the
SLE patients was 44 years (range, 22 /66 years). The
mean age of the control group was 42 years (range,
18 /65 years). The control group consisted of 30
women and three men. The diagnosis of SLE was
based on the revised criteria of the American College
of Rheumatology.
23 The mean duration of the disease
was 64 months (range, 8 months /20 years). Eighteen
patients had never been treated with steroids or
any other immunosuppressive agents. Thirty-five
patients were treated with prednisone at a dose of
5 /20 mguday during the study, including three
patients treated with prednisone and azatioprine at
a daily dose of 50 /100 mg.
Disease activity was scored according to the
method described by Liang et al.
24 Each patient
was examined on two separate occasions, 2 /4 weeks
apart. The system of Systemic Lupus Activity Measure
includes 24 clinical manifestations and eight labora-
tory parameters. The maximum score in this system is
84 points. We assumed a score of 0 /15 points for
inactive disease and a score over 15 points for active
disease.
25 By this definition, the active stage of the
disease was found in 22 patients while 31 patients
were in remission. Each patient underwent a thor-
ough physical examination performed by one of the
authors (E.R.). The patients with SLE and healthy
volunteers showed no clinical signs of infection or
neoplastic disease and received no other medications
for at least 4 weeks prior to blood donation. All
patients samples were collected between 08:00 and
14:00 h in the course of venipuncture for routine
laboratory investigations. This project was performed
in accordance with the Helsinki Declaration. In-
formed consent was obtained from all patients
participating in the study. The project was also
approved by the Local Ethic Committee.
Cell isolation
DCs were detected in peripheral blood mononuclear
cells (PBMC) population. Whole heparinized blood
samples were mixed with Hanks reagent (1:1),
and then centrifuged in the gradient of Ficoll-Paque
(2400 g for 20 min), then double-washed and re-
suspended in phosphate-buffered saline (PBS) buffer
(Sigma, St. Louis, MO, USA). Freshly isolated PBMC
were subjected to the immunophenotype examina-
tion.
Immunophenotyping
The immunophenotype of DCs was determined
using the panel of mAbs directed against several
DC-defined antigens. There were FITC-conjugated
BDCA-1, BDCA-2, and BDCA-3 (Miltenyi Biotec,
Bergish Gladbach, Germany), PE-conjugated CD11c,
CD32 (Caltag Laboratories, Burlingame, CA, USA)
and CD123 (Miltenyi Biotec), as well as TC-conju-
gated HLA-DR (Caltag Laboratories). In a preliminary
studies, combinations of another mAbs, against
CD14, CD19, and CD64 antigen, as well as CD80
and CD86 costimulatory molecules (all Caltag La-
boratories) were also tested. As a control, respective
mouse IgG1 mAbs MG101, MG104, MG106 were used
(Caltag Laboratories). Samples were prepared at the
concentration of 300,000 cellsu100 ml of PBS, in final
volume of 250 ml per sample. Antibodies were added
in the concentration of 1 mgu100 ml and incubated for
10 min at 48C, in the dark. Then, the immunophe-
notype was assessed by triple-color cytometry. Cell
fluorescence was measured by flow cytometer (FACS-
can; Becton-Dickinson, San Jose, CA, USA) and
analyzed with green (FL1), orange (FL2) or red
(FL3) standard emission filters. In each sample
100,000 events were acquired. Based on SC versus
FS distribution, DCs have been gated from a whole
PBMC population.
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calculating the absolute DC number
Based on preliminary studies, the characteristic
pattern of antigen expression of three main sub-
sets of DC were discriminated. There were two
myeloid subtypes of DCs: BDCA-1
 uCD11c
 uHLA-
DR
  (mDC1) and BDCA-3
 uCD32
 uHLA-DR
 
(mDC2), as well as pDC, characterized by the
BDCA-2
 uCD123
 u HLA-DR
  expression profile.
Determining the percentage of both myeloid sub-
populations with mAbs against CD14 and CD19
antigens for lineage negative selection (BDCA-
1
 uCD19
  for mDC1 and BDCA-3
 uCD14
  for
mDC2, respectively) gave consistent, comparable
results. The method of DC subtype discrimination
by flow cytometry is shown and described in Fig. 1,
using BDCA-2
 uCD123
  cell subset detection as an
example. For absolute DC count assessment, in every
patient and healthy volunteer the number of PBMC
per microliter was routinely measured. Then, based
on the percent of particular DC subset in the whole
PMBC population as determined by flow cytometry
(Fig. 1), the DC count was calculated and presented
as a number of cells per microliter.
Immunophenotype analysis of lymphocytes and
NK cells
Peripheral blood lymphocyte analysis was performed
by standard double-color immunofluorescence mea-
surement by flow cytometry. The details of the
procedure are described elsewhere.
26,27
Other clinical and laboratory features of SLE
The number of other clinical or laboratory SLE
features, such as the presence of arthritis, skin
lesions, reticuloendothelial system involvement, as
well as absolute leukocyte, lymphocyte and platelet
counts, serological symptoms, renal involvement,
presence of C-reactive protein, antinuclear antibodies
and erythrocyte sedimentation ratio were also routi-
nely assessed.
Statistical analysis
For the statistical analysis of the data the range of
measured variable (minimum /maximum), the mean
arithmetic value (x), the median (Me) and the
standard deviation (SD) were calculated. The
Shapiro /Wilk’s test was used to evaluate the dis-
tribution. In order to compare mean values, the
Mann /Whitney test, the test for two independent
samples or the Cochran /Cox test were applied. The
correlation between features was evaluated using the
Spearman rank coefficient r. Comparisons and cor-
relations were considered significant when pB /0.05.
Results
The total number of DCs and their subpopulations in
SLE patients and healthy donors
The number of circulating dendritic cells (tDC) and
their three main subpopulations (pDC, mDC1 and
mDC2) in peripheral blood was assessed in 53 SLE
patients and 33 healthy donors. The clinical and
laboratory characteristics of SLE patients are pre-
sented in Table 1.
FIG. 1. Detection of DCs by ﬂow cytometry. DCs have been
gated from the whole PBMC population based on the SC
versus FS distribution (black line). Then, in the gated cells
the expression of particular antigens were assessed by
triple-color ﬂow cytometry. In the shown case, distinct
BDCA-2
 uCD123
 uHLA-DR
  plasmacytoid DCs have been
discriminated. According to size (FS) and cellular density
(SC), the majority of pDC occurred between lymphocyte and
monocyte populations (dashed circle).
Table 1. Clinical and laboratory characteristics of patients
with SLE
Symptoms Number of
patients
)
Total 53 100.0
Age (years), mean (range) 43.9 (22 /66)
Sex (maleufemale) 4u49
Activeuinactive 22u31 41.5u58.5
Arthritis 49 92.5
Skin symptoms 44 83.0
Reticuloendothelial system
involvement
44 83.0
Renal disorder (creatinine
  /1.3 mgudl)
3 5.7
Neurologic symptoms 34 64.2
Antinuclear antibodies,
anti-dsDNA antibodies
7 13.2
Anemia (hemoglobinB /12 gudl) 13 24.5
Lymphopenia (B /1.5  /10
9ul) 25 47.2
Leukopenia (white blood cells
B /3.5  /10
9ul)
12 22.6
Thrombocytopenia (platelets
B /150  /10
9ul)
15 28.3
Raised erythrocyte sedimentation
ratio (  /25 mmuh)
32 60.4
C-reactive protein (  /4.7 mgul) 6 11.3
Treatment with steroids 35 60.0
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DC absolute values are presented in Table 2. The
mean number of tDC was lower in SLE patients
(13.99 /7.1uml) than in the control group (21.39 /
11.3uml) (pB /0.002). A comparable decrease in circu-
lating pDC (BDCA-2
 ) and mDC2 (BDCA-3
 ) sub-
types in SLE patients in relation to the normal control
group was observed (6.69 /3.7uml versus 11.49 /7.6uml,
pB /0.002 and 1.09 /1.1uml versus 2.39 /1.5uml, pB /
0.001, respectively). The absolute number of mDC1
(BDCA-1
 ) was similar in SLE patients and in healthy
donors (Table 2).
Correlation between DC number and circulating
T-cell, B-cell or NK subpopulations
The values of T CD3
 , T CD4
  and T CD8
 
subpopulations, NK cells and B cells are presented
in Table 3. No differences in the number of particular
subtypes of lymphocytes or NK cells in active and
inactive SLE patients were observed. Significant
positive correlations were also observed between T
CD4
  and tDC, pDC and mDC1 but not with the
mDC2 subpopulation (Fig. 2). Positive correlation
was also found between T CD8
  cells and tDC, pDC
Table 2. Analysis of peripheral blood dendritic cells in patients with SLE and healthy donors (cell uml)
Cell subpopulation All SLE
(n  /53) (a)
Active SLE
(n  /22) (b)
Inactive SLE
(n  /31) (c)
Control group
(n  /33) (d)
Statistically significant
comparison
tDCuml
x ¯9 /SD 13.99 /7.1 12.29 /6.1 15.19 /7.6 21.39 /11.3 (a) /(d), pB /0.002
Me 12.96 12.3 14.2 20.9 (b) /(d), pB /0.003
Range 2.5 /34.4 2.5 /24.8 5.3 /34.4 2.8 /48.3 (c) /(d), pB /0.02
pDC uml (a) /(d), pB /0.002
x ¯9 /SD 6.69 /3.7 5.59 /3.4 7.49 /3.7 11.49 /7.6 (b) /(c), pB /0.04
Me 6.0 5.4 6.9 10.0 (c) /(d), pB /0.002
Range 1.16 /18.0 1.2 /14.5 2.1 /18.0 0.0 /29.6 (c) /(d), pB /0.03
mDC1uml
x ¯9 /SD 6.39 /4.5 5.79 /3.9 6.79 /4.8 7.69 /5.8
Me 5.1 4.52 5.35 6.11
Range 0.9 /21.5 0.9 /14.8 1.9 /21.5 0.0 /21.5
mDC2uml
x ¯9 /SD 1.09 /1.1 1.19 /1.6 0.99 /0.6 2.39 /1.5 (a) /(d), pB /0.001
Me 0.8 0.7 0.9 2.3 (b) /(d), pB /0.001
Range 0.1 /7.8 0.1 /7.8 0.2 /2.9 0.0 /8.6 (c) /(d), pB /0.001
Table 3. Lymphocyte subpopulations in patients with SLE
Cell subpopulation All SLE
(n  /53)
Active SLE
(n  /22)
Inactive SLE
(n  /31)
TCD3  /cellsuml
x ¯9 /SD 1171.99 /582.7 1066.99 /506.6 1255.89 /634.7
Me 1066.5 924.2 1107.2
Range 477.4 /3480.0 477.4 /2309.5 576.8 /3480.0
TCD4  /cellsuml
x ¯9 /SD 684.19 /373.7 601.39 /320.3 750.49 /405.6
Me 603.4 477.21 660.0
Range 265.7 /2001.0 265.7 /1394.8 288.9 /2001.0
TCD8  /cellsuml
x ¯9 /SD 482.19 /262.3 434.09 /240.6 520.69 /277.2
Me 402.3 354.5 438.6
Range 159.9 /1418.1 159.9 /1230.7 218.0 /1418.1
NK  /cellsuml
x ¯9 /SD 43.49 /62.3 41.479 /66.19 45.19 /60.5
Me 11.92 12.08 11.44
Range 0.0 /216.5 1.46 /216.5 0.0 /204.9
Pan B (CD19  /) cellsuml
x ¯9 /s 150.29 /110.7 140.29 /112.0 158.19 /111.4
Me 121.6 107.0 164.8
Range 5.4 /548.1 11.3 /355.2 5.4 /548.10
p values are not significant between active and inactive SLE for all lymphocyte subpopulations.
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T CD8
  cells and mDC2 was not statistically sig-
nificant (p  /0.05). In contrast, tDC and pDC corre-
lated with CD19
  B cells but such correlation was
not observed with mDC (Fig. 4). Moreover, NK
(CD56
 ) cells did not correlate significantly with
DCs neither with a plasmacytoid nor with a myeloid
subpopulation (data not shown) (p  /0.05 for all
comparisons).
The number of DC subsets and SLE activity
The number of tDC in active and inactive SLE was
comparable (mean 12.29 /6.1uml and 15.19 /7.6uml,
respectively, p  /0.05) (Table 2). Similarly, the values
of mDC1 and mDC2 did not differ significantly in
patients with the disease flare and during remission.
Only the pDC number was lower in the active stage
(5.59 /3.4uml) than in the inactive stage of the disease
(7.49 /3.7uml) (pB /0.04).
The correlations between the disease activity score
and number of tDC, pDC and mDC were also
calculated (Fig. 5). Negative, but statistically not
significant, correlations were obtained for all com-
parisons (p  /0.05).
Correlation between DC number and particular
features of SLE
The DC number was also analyzed in comparison
with particular SLE features (Table 4). When
compared with patients with normal or elevated
number of lymphocytes or lymphocytes, we
observed significantly lower numbers of both tDC
and pDC in those with lymphopenia (both
pB /0.001) and leukopenia (pB /0.02 and pB /0.004,
respectively). Moreover, in patients with lymphope-
nia, a significantly lower number of mDC, but
only mDC1, was also found. We also compared
the number of DCs and their subpopulations with
other clinical or laboratory SLE features, such as
platelet number, arthritis, skin lesions, reticuloen-
dothelial system involvement, serological symptoms,
renal involvement, presence of C-reactive protein,
antinuclear antibodies and raised erythrocyte
sedimentation ratio. The differences were not statis-
tically significant (p  /0.05 for all comparisons). The
number of total DCs and their plasmacytic and
myeloid subpopulations were also similar in
the patients treated and untreated with steroids
(Table 4).
FIG. 2. Correlations between the number of T CD4
  cells and total dendritic cells (tDC) and their pDC and myeloid (mDC1 and
mDC2) subpopulations in the peripheral blood of SLE patients.
Dendritic cells in SLE
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  cells and total dendritic cells (tDC) and their pDC and myeloid (mDC1 and
mDC2) subpopulations in the peripheral blood of SLE patients.
FIG. 4. Correlations between the number of B CD19
  cells with total dendritic cells (tDC) and their pDC and myeloid (mDC1
and mDC2) subpopulations in the peripheral blood of SLE patients.
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In this study, the quantitative evaluation of peripheral
blood DCs and their particular subsets in patients
with SLE was performed in comparison with healthy
volunteers as a control. We showed that tDC, pDC
and mDC2 populations were significantly lower in
SLE patients than in healthy subjects. These observa-
tions are partially consistent with previous re-
ports.
21,28 Scheinecker et al. showed that the DC
count in patients with SLE was 50) lower than in the
control, regarding the number of CD11
  cells (mDC)
even 80) lower.
20 However, unlike those results, our
study showed a number of CD11
  mDC in SLE
patients similar to the healthy control. The reduction
in total DC count was clearly dependent on the
decrease in pDC and mDC2, the small subset of
myeloid BDCA3
  DCs. Most recently, a similar
finding was reported also by Blomberg et al.
14
The decrease in peripheral blood tDC number in
SLE patients was not unexpected. Accumulation of
DCs, especially pDC, in cutaneous lupus erythema-
tosus lesions has been previously shown in patients
with SLE.
17,29 Moreover, in SLE patients accelerated
migration of DCs to other sites of inflammation is also
possible. An alternative explanation might be that
pDC normally protect from autoimmune disease by
inducing tolerance, and in their absence T cells and
autoimmune T cells are more activated.
10,11
Another cause of decrease in DC number may be
prolonged treatment with prednisone, administered
to the majority of SLE patients. Peripheral blood pDC
from healthy people were previously found to be
very sensitive to steroids.
22 However, in our study the
numbers of both tDC and their subpopulations were
similar in patients treated and not treated with
prednisone (Table 4). Scheinecker et al. showed
negative correlation between the dose of steroids and
the DC count (r  /  /0.44, pB /0.04). The lack of
treatment-dependent differences in DC number in
our patients can be due to treatment with low doses
of prednisone (5 /20 mguday). Another possible
reason for the decrease in DC number is their
enhanced apoptosis. In in vitro studies, abnormal
apoptosis activation was found in lymphocytes from
SLE patients.
30,31
According to disturbances in circulating lympho-
cyte interactions observed in SLE patients,
3,4 we
correlated the total number of DCs and their subsets
with T-cell, B-cell and NK-cell subpopulations. Inter-
estingly, we found a simultaneous positive correla-
tion between the number of tDC, pDC and mDC1,
and both CD4
  and CD8
  T-cell count. Additionally,
with regard to tDC and pDC, distinct correlation with
the number of B cells was also found. These findings
strongly suggest complex interactions between those
cells, which probably play an important role in the
development of SLE. There was no correlation found
FIG. 5. Correlations between the disease activity score and number of total dendritic cells (tDC), pDC and mDC subpopulations
in peripheral blood of SLE patients.
Dendritic cells in SLE
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negative, but not statistically significant, correlation of
the number of tDC and their subsets with activity of
SLE assessed by the Systemic Lupus Activity Measure
scale. Similar results, although in distinctly smaller
groups of SLE patients, were described by Schei-
necker et al.
21 They showed that the tDC population
inversely correlated with the activity of the disease,
defined according to the European Consensus Lupus
Activity Measurement scale (r  /  /0.56, p  /0.01).
However, unlike our study, they did not correlate
the SLE activity with particular DC subpopulations.
In this study we compared the number of DC
subsets not only with SLE activity, but also with
several clinical and laboratory symptoms of the
disease. However, we found that only lymphocyte
and leukocyte counts influenced the number of DCs.
Namely, we showed that the tDC and pDC number
was significantly lower in patients with lymphopenia
or leukopenia than in those with normal lymphocyte
or leukocyte count, which clearly underlines the
origin of peripheral blood DCs, especially pDC.
Interestingly, in patients with lymphopenia a signifi-
cantly lower number of mDC, but only the mDC1
subpopulation, was also found. Thus, the number of
mDC2 was even relatively higher than in those
patients with normal or elevated leukocyteulympho-
cyte count. Positive correlation between total num-
bers of lymphocytes and DCs has been also observed
by other authors.
21 It should be stressed that in other
Table 4. Differences between the total number of peripheral blood dendritic cells (tDC) and their pDC and myeloid (mDC1,
mDC2) subpopulations in patients with and without selected SLE symptoms
SLE symptom n tDC pDC mDC1 mDC2
Lymphopenia LymphocytesB /1.5  /10
9ul2 5
x ¯9 /s 9.89 /4.7 4.39 /2.1 4.69 /3.3 1.09 /1.5
Me 9.2 3.9 3.8 0.63
Range 2.5 /20.1 1.2 /8.6 0.9 /14.8 0.1 /7.8
Lymphocytes] /1.5  /10
9ul2 8
x ¯9 /s 17.89 /7.0 8.89 /3.6 8.09 /4.9 1.09 /0.6
Me 15.9 7.3 6.2 0.9
Range 9.5 /34.4 4.5 /18.0 1.9 /21.5 0.2 /2.9
p value pB /0.001 pB /0.001 pB /0.002 p  /0.05
Leukopenia WBCB /3.5  /10
9ul1 2
x ¯9 /s 9.59 /5.2 4.09 /2.0 4.99 /4.0 0.69 /0.5
Me 10.1 4.10 3.70 0.60
Range 2.49 /20.06 1.16 /7.80 0.89 /14.81 0.13 /1.86
WBC] /3.5  /10
9ul4 1
x ¯9 /s 15.29 /7.2 7.49 /3.8 6.79 /4.6 1.19 /1.3
Me 14.36 6.75 5.33 0.87
Range 4.49 /34.44 2.20 /18.04 1.06 /21.50 0.19 /7.80
p value pB /0.02 pB /0.004 p  /0.05 p  /0.05
Thrombocytopenia PlateletsB /150  /10
9ul1 5
x ¯9 /s 11.69 /5.3 6.19 /3.4 4.99 /3.3 0.79 /0.3
Me 10.82 5.62 4.18 0.64
Range 4.49 /21.64 2.20 /14.52 1.06 /11.38 0.24 /1.36
Platelets] /150  /10
9ul3 8
x ¯9 /s 14.99 /7.7 6.89 /3.9 6.99 /4.8 1.19 /1.3
Me 13.91 6.53 5.53 0.91
Range 2.49 /34.44 1.16 /18.04 0.89 /21.50 0.13 /7.80
p value p  /0.05 p  /0.05 p  /0.05 p  /0.05
Treatment with steroids Steroids 35
x ¯9 /s 13.69 /7.3 6.49 /4.0 6.29 /4.4 1.09 /1.3
Me 12.81 5.36 5.00 0.80
Range 2.49 /34.44 1.16 /18.04 0.89 /19.35 0.13 /7.80
No steroids 18
x ¯9 /s 14.59 /6.8 7.19 /3.0 6.49 /4.6 1.09 /0.7
Me 13.61 6.97 5.26 0.88
Range 6.03 /31.37 2.36 /13.58 2.35 /21.50 0.19 /2.91
p value p  /0.05 p  /0.05 p  /0.05 p  /0.05
Values of DCs are in cellsuml.
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in advanced neoplastic diseases, a decrease in
peripheral blood DC count was also described.
32,33
There was no statistically significant relationship
to other laboratory or clinical features of SLE, such
as antinuclear antibodies level, anemia, thrombocy-
topenia, as well as the presence of skin, renal
or neurological symptoms, which could be due
to a small number of patients with particular SLE
symptoms.
To our best knowledge, this is the first complex
quantitative assessment and correlation of peripheral
blood DC subpopulations defined by a recently
developed panel of anti-BDCA mAbs, with detailed
clinical and laboratory characteristics of SLE patients.
According to recent findings, freshly isolated periph-
eral blood DCs can be divided into three main
subsets: pDC and two mDC subpopulations, mDC1
and mDC2. However, for several years peripheral
blood DCs have been defined by a variety of markers,
which still complicates their repeatable and compar-
able assessment. pDC are actually characterized as
cells expressing specific BDCA-2 and BDCA-4 anti-
gens, but they have also Lin
 , HLA-DR
 , CD123
 ,
CD11c
 , CD4
 , CD2
  and CD45RO
  characteris-
tics.
12,13
Previously, Upham et al. detected HLA-
DRuCD33
 -positive cells as a mDC subpopulation.
34
The frequency of CD33
  cells was similar to
the CD11c
  cell count. In the present approach
using BDCA antigens for DC assessment, the mDC1
are CD1c uBDCA-1
 , as well as Lin
 , HLA-DR
 ,
CD11c
bright, CD123
dim, CD4
 , CD45RO
 , CD2
 ,
and these cells express myeloid lineage markers
(CD13, CD33) as well as Fc receptors (CD32, CD64,
Fc RI). The second myeloid population, mDC2, is
BDCA-3-positive and expresses markers similar to
the mDC1, but they are simultaneously CD11c
low,
CD123
dim and CD2
 . Unlike CD1cuBDCA-1
  DCs,
they lack expression of Fc receptors like CD32, CD64
or Fc RI.
12,35 In this study, based on that know-
ledge and several preliminary measurements,
we established three sets of parameters that can
optimally characterize the main subsets of
DCs: BDCA-1
 uCD11c
 uHLA-DR
  (for mDC1),
BDCA-3
 uCD32
 uHLA-DR
  (for mDC2), and
BDCA-2
 uCD123
 uHLA-DR
  (for pDC).
Our data suggest that fluctuations in blood pDC
count in SLE patients are much more significant then
in mDC, especially in the main myeloid DC sub-
population, mDC1. We have also found that the pDC
count was lower in patients with active SLE com-
pared with non-active disease, whereas numbers of
mDC1 and mDC2 were similar in both groups.
Moreover, only tDC and pDC, but not mDC subsets,
correlated with B-cell count. DCs are considered a
crucial cells in regulation of immune response.
36,37
Plasmacytoid DCs are the main peripheral blood cells
producing IFN-a.
36,37 They also play a major role in
regulation of Th1 and Th2 cell response and partici-
pate in T-cell activation and tolerance.
38,39 In this
aspect, since an enhanced concentration of IFN-a has
an important role in the development of SLE, the
decreased number responsible for its production of
circulating DCs in patients with active phase of the
disease may be difficult to explain. In SLE patients,
however, DCs infiltrate skin involved in inflammatory
process, and probably also other tissues, and those
cells can be the main source of IFN-a.
17,29,40
In conclusion, this is the first assessment of the
absolute number of tDC, pDC and myeloid mDC1
and mDC1 subpopulations in SLE patients, with
special emphasis on the correlation with particular
clinical and laboratory feature. Our data suggest that
fluctuations of DC count in SLE patients’ blood are
much more significant in pDC than in mDC (espe-
cially in the main myeloid DC1 subset). The reduced
number of DCs in SLE patients can be caused by their
accelerated migration to the sites of inflammation
including skin lesions. Positive correlation between
DC number and TCD4
 , TCD8
  and CD19
  B cells
testifies to their interactions and influence on SLE
pathogenesis. The association between DC number
and clinical features seems to be less clear.
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